Rapid Acting Insulin Market will be US$ 11.17 Billion by 2032
The Global Rapid Acting Insulin Market will reach US$ 11.17 billion by 2032, up from US$ 7.36 billion in 2023, with a CAGR of 4.75 % between 2024 and 2032. Some of the key drivers driving the market include the rising risks of severity and mortality among patients, the general public's growing interest in customized medicine, and the rising costs associated with research and development (R&D) activities.